PubMed · 1997 · 182 citations · 5 references
MedicineOncologyPharmacologyApoptosisCancer PharmacologyMolecular OncologyApoptosis In CancerApoptosis RegulationApoptotic SignalingCancer Cell SignalingCell DeathRas Family OncogenesApoptosis Signaling In CancerApoptotic Signaling In CancerCancer Cell ApoptosisCell Death In CancerOncogenic Ras SignalingRas Signaling ActivationRas-targeted TherapiesTumor Cell Survival Pathways
Farnesyl transferase inhibitors (FTIs) are a novel class of antitumor drugs that block the oncogenic activity of Ras. Because FTIs lack significant cell toxicity in vitro and in vivo, a significant question is how they cause tumor regression. We now report that FTIs are in fact potent activators of apoptosis in Ras-transformed cells if attachment to substratum is prevented. When cultured at high density or on polyHEMA, a nonadherent substrate, Ras-transformed cells exhibited massive DNA degradation and cell death within 24 h of treatment with the FTI L-739,749. Death was p53-independent and was inhibited by the apoptosis suppressor BCL-XL. Furthermore, apoptosis was significantly attenuated by ectopic expression of a farnesyl-independent form of RhoB, a Rho protein previously implicated as a critical target for inhibition by FTIs. The findings suggest a link between FTIs and Rho-dependent adhesion signaling. Furthermore, our work indicates that FTIs revert cells to a state in which cell-substratum attachment is necessary for viability and suggests that apoptosis forms the basis for drug-induced tumor regression.
5
Antibodies, a laboratory manual
Biomedicine & Pharmacotherapy · 1989 · 12.5K citations
A role for Rho in Ras transformation.
Rongyan Qiu, Jianfei Chen, Frank McCormick et al. · Proceedings of the National Academy of Sciences · 1995 · 534 citations
Critical role of Rho in cell transformation by oncogenic Ras.
George C. Prendergast, Roya Khosravi‐Far, Patricia A. Solski et al. · PubMed · 1995 · 253 citations